Ultrasensitive Detection of Alzheimer's Amyloids on a Plasmonic-Gold Platform

Hsiao Fen Han; Hung Chi Yen; Hsiu Chuan Wu; Hsin Yuan Tan; Wei Xu; Hang Shiang Jiang; Ping Jui Tsai; Kun Qian; Yi Chun Wu; Chia Chun Chen

doi:10.1021/acsami.1c19157

Ultrasensitive Detection of Alzheimer's Amyloids on a Plasmonic-Gold Platform

Hsiao Fen Han, Hung Chi Yen, Hsiu Chuan Wu, Hsin Yuan Tan, Wei Xu, Hang Shiang Jiang, Ping Jui Tsai, Kun Qian, Yi Chun Wu^*, Chia Chun Chen^*

^*Corresponding author for this work

Department of Chemistry

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

More than 55 million people live with dementia worldwide in 2021, and there are nearly 10 million new cases every year. Alzheimer's disease (AD) is the most common cause of dementia. Despite urgent need, early detection of AD and long-term monitoring of AD progression have been challenging. This is due to the limited availability of brain imaging facilities and the highly invasive procedure with the cerebrospinal fluid assay to assess the level of AD biomarkers, such as beta-amyloid (Aβ). Reliable measurements of AD biomarkers in blood samples are still difficult because of their very low abundance. Here, we develop a rapid, specific, and ultrasensitive immunoassay using plasmonic-gold nanoisland (pGOLD) chips with near-infrared fluorescence-enhanced detection for Aβ1-40 and Aβ1-42. We show step-by-step processes and results during the platform establishment, including antibody specificity and sensitivity tests, antibody pair examination, condition optimization, and procedure refinement. Finally, we demonstrate the platform performance with detection sensitivity at the subpicogram per milliliter level. This platform, therefore, has a great application potential for early detection of AD using blood samples.

Original language	English
Pages (from-to)	57036-57042
Number of pages	7
Journal	ACS Applied Materials and Interfaces
Volume	13
Issue number	48
DOIs	https://doi.org/10.1021/acsami.1c19157
Publication status	Published - 2021 Dec 8

Keywords

Alzheimer's disease
beta-amyloid
blood biomarkers
plasmonic-gold chip
surface plasmon-enhanced fluorescence

ASJC Scopus subject areas

General Materials Science

Access to Document

10.1021/acsami.1c19157

Cite this

@article{768033cb6ece432ea5827232796a6341,

title = "Ultrasensitive Detection of Alzheimer's Amyloids on a Plasmonic-Gold Platform",

abstract = "More than 55 million people live with dementia worldwide in 2021, and there are nearly 10 million new cases every year. Alzheimer's disease (AD) is the most common cause of dementia. Despite urgent need, early detection of AD and long-term monitoring of AD progression have been challenging. This is due to the limited availability of brain imaging facilities and the highly invasive procedure with the cerebrospinal fluid assay to assess the level of AD biomarkers, such as beta-amyloid (Aβ). Reliable measurements of AD biomarkers in blood samples are still difficult because of their very low abundance. Here, we develop a rapid, specific, and ultrasensitive immunoassay using plasmonic-gold nanoisland (pGOLD) chips with near-infrared fluorescence-enhanced detection for Aβ1-40 and Aβ1-42. We show step-by-step processes and results during the platform establishment, including antibody specificity and sensitivity tests, antibody pair examination, condition optimization, and procedure refinement. Finally, we demonstrate the platform performance with detection sensitivity at the subpicogram per milliliter level. This platform, therefore, has a great application potential for early detection of AD using blood samples.",

keywords = "Alzheimer's disease, beta-amyloid, blood biomarkers, plasmonic-gold chip, surface plasmon-enhanced fluorescence",

author = "Han, {Hsiao Fen} and Yen, {Hung Chi} and Wu, {Hsiu Chuan} and Tan, {Hsin Yuan} and Wei Xu and Jiang, {Hang Shiang} and Tsai, {Ping Jui} and Kun Qian and Wu, {Yi Chun} and Chen, {Chia Chun}",

note = "Publisher Copyright: {\textcopyright} 2021 American Chemical Society.",

year = "2021",

month = dec,

day = "8",

doi = "10.1021/acsami.1c19157",

language = "English",

volume = "13",

pages = "57036--57042",

journal = "ACS Applied Materials and Interfaces",

issn = "1944-8244",

publisher = "American Chemical Society",

number = "48",

}

TY - JOUR

T1 - Ultrasensitive Detection of Alzheimer's Amyloids on a Plasmonic-Gold Platform

AU - Han, Hsiao Fen

AU - Yen, Hung Chi

AU - Wu, Hsiu Chuan

AU - Tan, Hsin Yuan

AU - Xu, Wei

AU - Jiang, Hang Shiang

AU - Tsai, Ping Jui

AU - Qian, Kun

AU - Wu, Yi Chun

AU - Chen, Chia Chun

PY - 2021/12/8

Y1 - 2021/12/8

N2 - More than 55 million people live with dementia worldwide in 2021, and there are nearly 10 million new cases every year. Alzheimer's disease (AD) is the most common cause of dementia. Despite urgent need, early detection of AD and long-term monitoring of AD progression have been challenging. This is due to the limited availability of brain imaging facilities and the highly invasive procedure with the cerebrospinal fluid assay to assess the level of AD biomarkers, such as beta-amyloid (Aβ). Reliable measurements of AD biomarkers in blood samples are still difficult because of their very low abundance. Here, we develop a rapid, specific, and ultrasensitive immunoassay using plasmonic-gold nanoisland (pGOLD) chips with near-infrared fluorescence-enhanced detection for Aβ1-40 and Aβ1-42. We show step-by-step processes and results during the platform establishment, including antibody specificity and sensitivity tests, antibody pair examination, condition optimization, and procedure refinement. Finally, we demonstrate the platform performance with detection sensitivity at the subpicogram per milliliter level. This platform, therefore, has a great application potential for early detection of AD using blood samples.

AB - More than 55 million people live with dementia worldwide in 2021, and there are nearly 10 million new cases every year. Alzheimer's disease (AD) is the most common cause of dementia. Despite urgent need, early detection of AD and long-term monitoring of AD progression have been challenging. This is due to the limited availability of brain imaging facilities and the highly invasive procedure with the cerebrospinal fluid assay to assess the level of AD biomarkers, such as beta-amyloid (Aβ). Reliable measurements of AD biomarkers in blood samples are still difficult because of their very low abundance. Here, we develop a rapid, specific, and ultrasensitive immunoassay using plasmonic-gold nanoisland (pGOLD) chips with near-infrared fluorescence-enhanced detection for Aβ1-40 and Aβ1-42. We show step-by-step processes and results during the platform establishment, including antibody specificity and sensitivity tests, antibody pair examination, condition optimization, and procedure refinement. Finally, we demonstrate the platform performance with detection sensitivity at the subpicogram per milliliter level. This platform, therefore, has a great application potential for early detection of AD using blood samples.

KW - Alzheimer's disease

KW - beta-amyloid

KW - blood biomarkers

KW - plasmonic-gold chip

KW - surface plasmon-enhanced fluorescence

UR - http://www.scopus.com/inward/record.url?scp=85120649251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120649251&partnerID=8YFLogxK

U2 - 10.1021/acsami.1c19157

DO - 10.1021/acsami.1c19157

M3 - Article

C2 - 34843217

AN - SCOPUS:85120649251

SN - 1944-8244

VL - 13

SP - 57036

EP - 57042

JO - ACS Applied Materials and Interfaces

JF - ACS Applied Materials and Interfaces

IS - 48

ER -

Ultrasensitive Detection of Alzheimer's Amyloids on a Plasmonic-Gold Platform

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this